Pepinemab

派比奈单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePepinemab
Drug Alias NameAnti-SEMA4D monoclonal antibody - VaccinexmoAb VX-15/2503VX-15/2503VX-15
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSemaphorin 4D inhibitors
TargetsSemaphorin 4D
Therapy Area/IndicationsSkin MelanomaSolid tumoursAlzheimer Disease +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVaccinex Inc
China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research InstituteNational Cancer InstituteVaccinex Inc +[4] 
Inactive CompaniesN/A
Active IndicationsSkin MelanomaSolid tumoursAlzheimer Disease +[9] 
Inactive IndicationsHuntington DiseaseMultiple SclerosisCarcinoma, Non-Small-Cell Lung +[4] 

Other Information

ATC CodeN/A
Related LinksN/A